Anzeige
Meldung des Tages: Goldaktie mit Nachholpotenzial: Über 2 Mio. Unzen Gold – und trotzdem erst 59 Mio. USD Börsenwert?

BeOne Medicines Aktie (ADR) News

Aktie
WKN:  A1437N ISIN:  US07725L1026 US-Symbol:  ONC Branche:  Biotechnologie Land:  Schweiz
284,00 €
-8,00 €
-2,74%
10:47:12 Uhr
Depot/Watchlist
Marktkapitalisierung *
28,99 Mrd. €
Streubesitz
51,65%
KGV
91,18
Faktor
0.0769231
Originalaktie
CH1391448177
neu: Nachhaltigkeits-Score
20 %
Weiter abwärts? Short handeln - Jetzt mit Hebel 5,38: MM2KYV
Werbung

BeOne Medicines Aktie (ADR) News

23.05.25 - PR Newswire
New Data and Deal Flow Signal a Turning Point for Precision-Driven Cancer Biotechs
New Data and Deal Flow Signal a Turning Point for Precision-​Driven Cancer Biotechs PR Newswire
23.05.25 - PR Newswire
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities
Oncolytics Biotech® to Present New Clinical Trial Data at ASCO Showing Pelareorep's Unique Immune Activation Capabilities PR Newswire
14.05.25 - PR Newswire
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum
Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum PR Newswire
06.05.25 - PR Newswire
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech® to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights PR Newswire
01.05.25 - PR Newswire
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty PR Newswire
01.05.25 - PR Newswire
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty
New Cancer Treatments Spark Hope as Traditional Funding Faces Uncertainty PR Newswire
14.04.25 - PR Newswire
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz PR Newswire
14.04.25 - PR Newswire
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz
With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz PR Newswire
10.04.25 - PR Newswire
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital
Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital PR Newswire
10.04.25 - PR Newswire
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers
Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers PR ...
08.03.25 - PR Newswire
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge
Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge PR Newswire
07.03.25 - PR Newswire
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024
Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024 PR Newswire
27.02.25 - PR Newswire
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire
27.02.25 - PR Newswire
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025
Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire
25.02.25 - PR Newswire
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights PR Newswire
19.02.25 - PR Newswire
Investors Eye Biotech Sector as Cancer Therapy Market Surges
Investors Eye Biotech Sector as Cancer Therapy Market Surges PR Newswire
19.02.25 - PR Newswire
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025
Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025 PR Newswire
18.02.25 - PR Newswire
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer
Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer PR Newswire
14.02.25 - PR Newswire
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency PR Newswire
07.02.25 - PR Newswire
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence
Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence PR Newswire

Newssuche

Videos

newspaper
29.01.26 -6,42%
Rekordjagd bei Gold! Februar Ausblick & Forecast
Ab 2.2. (Montag) börsentäglich um 18 Uhr FEIERABEND-​TRADING. Echte Trades, strategiebasiert, ... Mehr »
Anzeige

Aktie im Fokus

Durchbruch bei Drohnen-Batterien
NEO Battery Materials Ltd
0,422 €
+4,46%
NEO Battery Materials Ltd Chart
Diese Nachricht schockt den Markt
Mehr zur Aktie »